These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 2894284)

  • 1. WHO Symposium on Drug Dependence: Benefit-risk ratio assessment of agonist-antagonist analgesics. August 1986. Satellite meeting to the III World Conference on Clinical Pharmacology and Therapeutics.
    Drug Alcohol Depend; 1987 Dec; 20(4):289-399. PubMed ID: 2894284
    [No Abstract]   [Full Text] [Related]  

  • 2. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interactions between naltrexone, an opioid antagonist, and opioids administered during general anesthesia].
    Tesson B; Bigot-Viale A; Vigue JP; Pierrot M; Granry JC
    Ann Fr Anesth Reanim; 1999 Feb; 18(2):230-2. PubMed ID: 10207596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit-risk ratio of agonist-antagonist analgesics.
    Lasagna L
    Drug Alcohol Depend; 1987 Dec; 20(4):385-93. PubMed ID: 2894291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
    Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
    J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of the dependence-producing potential of the narcotic antagonist 2-cyclopropylmethyl-2'-hydroxy-5,9-dimethyl-6,7-benzomorphan (cyclazocine, WIN-20,740, ARC II-c-3).
    Martin WR; Fraser HF; Gorodetzky CW; Rosenberg DE
    J Pharmacol Exp Ther; 1965 Dec; 150(3):426-36. PubMed ID: 5322320
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans.
    Carroll CP; Walsh SL; Bigelow GE; Strain EC; Preston KL
    Exp Clin Psychopharmacol; 2006 May; 14(2):109-20. PubMed ID: 16756415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methodology for the evaluation of pentazocine, prototype of the new morphine agonist-antagonist analgesics.
    Seevers MH
    Int J Clin Pharmacol; 1974 Apr; 7(3):167-73. PubMed ID: 4212164
    [No Abstract]   [Full Text] [Related]  

  • 9. Discrimination of a single dose of morphine followed by naltrexone: substitution of other agonists for morphine and other antagonists for naltrexone in a rat model of acute dependence.
    Holtzman SG
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1033-41. PubMed ID: 12604679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opiate receptor pharmacology: mixed agonist/antagonist narcotics.
    Hameroff SR
    Contemp Anesth Pract; 1983; 7():27-43. PubMed ID: 6136392
    [No Abstract]   [Full Text] [Related]  

  • 11. Tramadol: new preparation. Capsules: central analgesic; step 2 on the WHO scale.
    Prescrire Int; 1998 Feb; 7(33):9-12. PubMed ID: 10183392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine for opioid dependence.
    Milne M; Crouch BI; Caravati EM
    J Pain Palliat Care Pharmacother; 2009; 23(2):153-5. PubMed ID: 19492216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats.
    Schiller PW; Fundytus ME; Merovitz L; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Coderre TJ
    J Med Chem; 1999 Sep; 42(18):3520-6. PubMed ID: 10479285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug utilization in relation to morbidity. Proceedings from a symposium held at the III World Conference on Clinical Pharmacology and Therapeutics. Stockholm, July 27-August 1, 1986.
    Acta Med Scand Suppl; 1988; 721():1-35. PubMed ID: 3162629
    [No Abstract]   [Full Text] [Related]  

  • 15. Medicines and the drug control treaties: is buprenorphine for opioid addiction at risk of being lost?
    Costa E Silva JA
    Hum Psychopharmacol; 2004 Jun; 19(4):215-24. PubMed ID: 15181649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dependence studies of new compounds in the rhesus monkey, rat and mouse (1997).
    Aceto MD; Bowman ER; Harris LS; May EL
    NIDA Res Monogr; 1998 Mar; 178():363-407. PubMed ID: 9686404
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
    Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
    J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dependence characteristics and risk assessment of agonist-antagonist analgesics.
    Yanagita T
    Drug Alcohol Depend; 1987 Dec; 20(4):317-27. PubMed ID: 2894286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tolerance and dependence on opioid analgesics: experimental and clinical aspects].
    Le Bars M; Glowinski J; Bannwarth B
    Therapie; 2000; 55(3):343-7. PubMed ID: 10967710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basic pharmacology relevant to drug abuse assessment: tramadol as example.
    Raffa RB
    J Clin Pharm Ther; 2008 Apr; 33(2):101-8. PubMed ID: 18315774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.